Stock of the Day

Novartis (NVS)

$150.34

+$3.46 (+2.4%)

Market Cap: $280.27B

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians.

It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Novartis Bull Case

Here are some ways that investors could benefit from investing in Novartis AG:

• Novartis AG recently secured FDA approval for Rhapsido (remibrutinib) for symptomatic dermographism, marking the first treatment for this condition and expanding the drug's commercial potential beyond chronic spontaneous urticaria, which is a significant catalyst for growth in the immunology sector.
• The company reported positive Phase III results for remibrutinib in relapsing multiple sclerosis, suggesting a broader therapeutic application that could drive future revenue, with an investor call scheduled for October 23, 2026, to discuss this program further.
• Novartis AG demonstrated strong financial performance in its most recent quarter, reporting earnings per share of $2.41 and revenue of $14.95 billion, with a net margin of 23.29% and a return on equity of 38.56%, indicating robust profitability and efficient capital management.
• With a current stock price of $146.94, the stock is trading near its 52-week high of $170.46 and significantly above its 52-week low of $121.57, reflecting strong investor confidence and momentum in the pharmaceutical sector.
• The company offers a dividend yield of 2.14%, providing a steady income stream for investors, while its low beta of 0.41 suggests lower volatility compared to the broader market, making it a potentially stable addition to a diversified portfolio.

Novartis Bear Case

Investors should be bearish about investing in Novartis AG for these reasons:

• Erste Group Bank recently cut its FY2027 earnings per share estimate for Novartis AG to $9.80 from $9.81, signaling potential concerns about future earnings growth, although the consensus estimate remains at $8.91 per share.
• The stock has a price-to-earnings ratio of 22.16, which is relatively high compared to some peers, and the consensus rating from analysts is "Hold" with a target price of $145.60, suggesting limited upside potential from the current price of $146.94.
• Novartis AG has a debt-to-equity ratio of 0.89 and a current ratio of 0.86, indicating that the company has more short-term liabilities than current assets, which could pose liquidity risks if cash flow tightens.
• Short interest in Novartis AG increased by 8.24% in the most recent month to 5,624,031 shares, with days to cover at 2.93, suggesting that some investors are betting against the stock, which could lead to downward pressure on the price.
• Pomerantz Law Firm is investigating claims on behalf of investors of Novartis AG, which could lead to legal costs and reputational damage, potentially impacting the company's financial performance and stock price.

Recent News

• Why Novartis (NVS) Stock Is Up Today (quiverquant.com)
• ClearBridge Appreciation Strategy adds new positions in Mastercard, Novartis; exits Disney, Cisco, SPCX among Q3 moves (msn.com)
• INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS (globenewswire.com)